- Home
- TECH vs IONS Comparison
TECH vs IONS Comparison
Compare TECH & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECH
- IONS
- Stock Information
- Founded
- TECH 1976
- IONS 1989
- Country
- TECH United States
- IONS United States
- Employees
- TECH N/A
- IONS N/A
- Industry
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- TECH Health Care
- IONS Health Care
- Exchange
- TECH Nasdaq
- IONS Nasdaq
- Market Cap
- TECH 8.3B
- IONS 6.8B
- IPO Year
- TECH 1989
- IONS 1991
- Fundamental
- Price
- TECH $51.26
- IONS $63.16
- Analyst Decision
- TECH Buy
- IONS Buy
- Analyst Count
- TECH 12
- IONS 17
- Target Price
- TECH $70.91
- IONS $67.88
- AVG Volume (30 Days)
- TECH 2.0M
- IONS 3.3M
- Earning Date
- TECH 10-29-2025
- IONS 11-05-2025
- Dividend Yield
- TECH 0.62%
- IONS N/A
- EPS Growth
- TECH N/A
- IONS N/A
- EPS
- TECH 0.46
- IONS N/A
- Revenue
- TECH $1,219,635,000.00
- IONS $944,050,000.00
- Revenue This Year
- TECH $4.13
- IONS $24.30
- Revenue Next Year
- TECH $7.56
- IONS $7.39
- P/E Ratio
- TECH $111.46
- IONS N/A
- Revenue Growth
- TECH 5.23
- IONS 16.05
- 52 Week Low
- TECH $46.01
- IONS $23.95
- 52 Week High
- TECH $80.95
- IONS $64.72
- Technical
- Relative Strength Index (RSI)
- TECH 42.09
- IONS 79.95
- Support Level
- TECH $50.87
- IONS $62.79
- Resistance Level
- TECH $54.62
- IONS $64.72
- Average True Range (ATR)
- TECH 1.85
- IONS 2.29
- MACD
- TECH -0.37
- IONS 1.49
- Stochastic Oscillator
- TECH 7.31
- IONS 93.22
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.